{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:18:43Z","timestamp":1789697923180,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier","isbn-type":[{"value":"9780443235443","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmbts.2023.12.005","type":"book-chapter","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:54:31Z","timestamp":1703814871000},"page":"45-67","source":"Crossref","is-referenced-by-count":3,"title":["An update on the therapeutic role of RNAi in NAFLD\/NASH"],"prefix":"10.1016","member":"78","reference":[{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.005_bib2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.005_bib4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/bs.pmbts.2023.12.005_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13331","article-title":"Genetic predisposition in metabolic\u2010dysfunction\u2010associated fatty liver disease and cardiovascular outcomes\u2014systematic review","volume":"50","author":"Ismaiel","year":"2020","journal-title":"Eur J Clin Investig"},{"issue":"12","key":"10.1016\/bs.pmbts.2023.12.005_bib6","doi-asserted-by":"crossref","first-page":"9819","DOI":"10.1002\/jcp.29795","article-title":"Long noncoding RNA CCAT1 inhibits miR\u2010613 to promote nonalcoholic fatty liver disease via increasing LXR\u03b1 transcription","volume":"235","author":"Huang","year":"2020","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","article-title":"Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease","volume":"76","author":"Guo","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12525","article-title":"The impact of health status, diet and lifestyle on non\u2010alcoholic fatty liver disease: narrative review","volume":"12","author":"Alalwani","year":"2022","journal-title":"Clin Obes"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.ymthe.2021.11.007","article-title":"An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis","volume":"30","author":"Yenilmez","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: state of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8936865","article-title":"GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"2021","author":"Rezaei","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.005_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/nu14071331","article-title":"Investigation of the effect of curcumin on protein targets in NAFLD using bioinformatic analysis","volume":"14","author":"Mahmoudi","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"4041415","DOI":"10.1155\/2021\/4041415","article-title":"The emerging role of nanomedicine in the management of nonalcoholic fatty liver disease: a state-of-the-art review","volume":"2021","author":"Moosavian","year":"2021","journal-title":"Bioinorg Chem Appl"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"3654660","DOI":"10.1155\/2021\/3654660","article-title":"Target deconvolution of fenofibrate in nonalcoholic fatty liver disease using bioinformatics analysis","volume":"2021","author":"Mahmoudi","year":"2021","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.005_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur J Nutr"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.","volume":"233","author":"Derosa","year":"2018","journal-title":"Journal of cellular physiology,"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13543784.2021.1879792","article-title":"A perspective on RNA interference-based therapeutics for metabolic liver diseases","volume":"30","author":"Alkhouri","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering Technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J Pharmacol Exp Therapeutics"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N Engl J Med"},{"issue":"5-6","key":"10.1016\/bs.pmbts.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10529-022-03249-8","article-title":"Calumenin knockdown, by intronic artificial microRNA, to improve expression efficiency of the recombinant human coagulation factor IX","volume":"44","author":"Parnian","year":"2022","journal-title":"Biotechnol Lett"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol Therapy-Nucleic Acids"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight into the prospects for RNAi therapy of cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/s41598-018-37209-y","article-title":"Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH","volume":"9","author":"Torquato","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.4103\/ijpvm.IJPVM_274_19","article-title":"Predictors of nonalcoholic fatty liver disease among middle-aged Iranians","volume":"11","author":"Etminani","year":"2020","journal-title":"Int J Prev Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/liv.14038","article-title":"Prevalence and outcomes of non\u2010alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States","volume":"39","author":"Golabi","year":"2019","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.005_bib28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.005_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clnu.2019.02.024","article-title":"Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: a population-based study of northern Iran","volume":"39","author":"Motamed","year":"2020","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib31","first-page":"2022","article-title":"The risk factors of nonalcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery in Iran","author":"Aghakhani","year":"2022","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12937-020-00580-6","article-title":"Association of the dietary patterns with the risk of non-alcoholic fatty liver disease among Iranian population: a case-control study","volume":"19","author":"Dehghanseresht","year":"2020","journal-title":"Nutr J"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MEG.0000000000002288","article-title":"Healthcare practitioners\u2019 diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey","volume":"34","author":"Hartleb","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601745","article-title":"Integrated multichip analysis identifies potential key genes in the pathogenesis of nonalcoholic steatohepatitis","volume":"11","author":"Ye","year":"2020","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10715762.2019.1608982","article-title":"Evaluation of the therapeutic potential effect of Fas receptor gene knockdown in experimental model of non-alcoholic steatohepatitis","volume":"53","author":"Savari","year":"2019","journal-title":"Free Radic Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib36","article-title":"Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Yasar","year":"2022","journal-title":"BMJ Health Care Inf"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5604\/01.3001.0011.7395","article-title":"Therapeutic effect of HGF on NASH mice through HGF\/c-Met and JAK2-STAT3 signalling pathway","volume":"17","author":"Li","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib38","article-title":"Higher consumption of animal organ meat is associated with a lower prevalence of nonalcoholic steatohepatitis","author":"Zhang","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1-4","key":"10.1016\/bs.pmbts.2023.12.005_bib39","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ddmec.2009.02.002","article-title":"Mitochondrial dysfunction in nonalcoholic steatohepatitis (NASH): are there drugs able to improve it?","volume":"6","author":"Begriche","year":"2009","journal-title":"Drug Discov Today: Dis Mech"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2015.11.002","article-title":"Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis","volume":"64","author":"Eguchi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib41","article-title":"Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children","author":"Goyal","year":"2022","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/bs.pmbts.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3390\/cells9102247","article-title":"Discovery and targeting of the signaling controls of PNPLA3 to effectively reduce transcription, expression, and function in pre-clinical NAFLD\/NASH settings","volume":"9","author":"Schwartz","year":"2020","journal-title":"Cells"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib43","article-title":"Nanomedicines for hepatocellular carcinoma therapy: Challenges and clinical applications","volume":"34","author":"Sedighi","year":"2023","journal-title":"Mater Today Commun"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7251450","article-title":"Pharmacological mechanism of ganlu powder in the treatment of NASH based on network pharmacology and molecular docking","volume":"2022","author":"Gao","year":"2022","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.005_bib46","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.aohep.2020.08.066","article-title":"Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population","volume":"19","author":"Zambrano-Huailla","year":"2020","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cgh.2019.07.036","article-title":"Clinically significant fibrosis is associated with longitudinal increases in fibrosis-4 and nonalcoholic fatty liver disease fibrosis scores","volume":"18","author":"Patel","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.005_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260320","article-title":"Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)","volume":"16","author":"Eskridge","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.pmbts.2023.12.005_bib51","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200111R","article-title":"Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr\u2212\/\u2212. Leiden mice with manifest obesity\u2010associated NASH","volume":"36","author":"Gart","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fphys.2016.00553","article-title":"RNAi efficiency, systemic properties, and novel delivery methods for pest insect control: what we know so far","volume":"7","author":"Joga","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2014.07.056","article-title":"Current issues of RNAi therapeutics delivery and development","volume":"195","author":"Haussecker","year":"2014","journal-title":"J Controlled Rel"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci China Life Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.005_bib55","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","article-title":"Where should siRNAs go: applicable organs for siRNA drugs","volume":"55","author":"Ahn","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.toxrep.2023.01.007","article-title":"Role of miRNAs in mediating organophosphate compounds induced toxicity","volume":"10","author":"Dehghan","year":"2023","journal-title":"Toxicol Rep"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib57","first-page":"1","article-title":"microRNAs in action: biogenesis, function and regulation","author":"Shang","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.celrep.2013.12.013","article-title":"RNAi factors are present and active in human cell nuclei","volume":"6","author":"Gagnon","year":"2014","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib59","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/jcp.30699","article-title":"The role of exosomal miRNA in nonalcoholic fatty liver disease","volume":"237","author":"Mahmoudi","year":"2022","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib61","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3389\/fpls.2019.01023","article-title":"siRNA-Finder (si-Fi) software for RNAi-target design and off-target prediction","volume":"10","author":"L\u00fcck","year":"2019","journal-title":"Front Plant Sci"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib62","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fbioe.2020.00916","article-title":"Prospects for RNAi therapy of COVID-19","volume":"8","author":"Uluda\u011f","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymeth.2016.04.003","article-title":"Guidelines for the optimal design of miRNA-based shRNAs","volume":"103","author":"Bofill-De Ros","year":"2016","journal-title":"Methods"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cgt.2016.4","article-title":"Precise and efficient siRNA design: a key point in competent gene silencing","volume":"23","author":"Fakhr","year":"2016","journal-title":"Cancer Gene Ther"},{"issue":"49","key":"10.1016\/bs.pmbts.2023.12.005_bib65","doi-asserted-by":"crossref","first-page":"1903637","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv Mater"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.005_bib66","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/polym15051160","article-title":"Multifunctional self-assembled peptide hydrogels for biomedical applications","volume":"15","author":"Sedighi","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2022.12.058","article-title":"Nanostructured multifunctional stimuli-responsive glycopolypeptide-based copolymers for biomedical applications","volume":"354","author":"Sedighi","year":"2023","journal-title":"J Controlled Rel"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.005_bib68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.molmet.2016.08.004","article-title":"Inhibition of citrate cotransporter Slc13a5\/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice","volume":"5","author":"Brachs","year":"2016","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.005_bib69","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/odi.13153","article-title":"Porphyromonas gingivalis\u2010derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF\u2010\u03baB and JNK signaling pathways","volume":"25","author":"Ding","year":"2019","journal-title":"Oral Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/lt.25383","article-title":"Gene silencing with siRNA (RNA interference): a new therapeutic option during ex vivo machine liver perfusion preservation","volume":"25","author":"Thijssen","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.005_bib72","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/nat.2021.0026","article-title":"Identification and optimization of a minor allele-specific siRNA to prevent PNPLA3 I148M-driven nonalcoholic fatty liver disease","volume":"31","author":"Murray","year":"2021","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101566","article-title":"The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR","volume":"64","author":"Steffen","year":"2022","journal-title":"Mol Metab"},{"issue":"9","key":"10.1016\/bs.pmbts.2023.12.005_bib74","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/hep4.1405","article-title":"A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","author":"Kara","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"issue":"49","key":"10.1016\/bs.pmbts.2023.12.005_bib78","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.005_bib79","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in Iranian patients","volume":"22","author":"Eshraghian","year":"2017","journal-title":"Iran J Gastroenterol Hepatol (Govaresh)"},{"issue":"22","key":"10.1016\/bs.pmbts.2023.12.005_bib80","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"Jama"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib81","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/hep.31428","article-title":"An endoplasmic reticulum stress\u2013micro RNA\u201026a feedback circuit in NAFLD","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-11-172","article-title":"Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease","volume":"11","author":"Hotta","year":"2010","journal-title":"BMC Med Genet"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib83","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1002\/hep.32063","article-title":"Modeling PNPLA3\u2013associated NAFLD using human\u2010induced pluripotent stem cells","volume":"74","author":"Tilson","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib84","doi-asserted-by":"crossref","unstructured":"Li P, Shan K, Liu Y, Zhang Y, Xu L, Xu L. IDDF2018-ABS-0074 CIRCSCD1 Promotes Fatty Liver Disease via the Janus Kinase 2\/Signal Transducer and Activator of Transcription 5 Pathway. BMJ Publishing Group; 2018.","DOI":"10.1136\/gutjnl-2018-IDDFabstracts.46"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10620-018-5290-2","article-title":"CircScd1 promotes fatty liver disease via the janus kinase 2\/signal transducer and activator of transcription 5 pathway","volume":"64","author":"Li","year":"2019","journal-title":"Digest Dis Sci"},{"key":"10.1016\/bs.pmbts.2023.12.005_bib86","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00394-017-1472-5","article-title":"High-fat diet inhibits PGC-1\u03b1 suppressive effect on NF\u03baB signaling in hepatocytes","volume":"57","author":"Barroso","year":"2018","journal-title":"Eur J Nutr"},{"issue":"Suppl. 1","key":"10.1016\/bs.pmbts.2023.12.005_bib87","article-title":"839-P: pharmacological inhibition of mammalian INDY ameliorates western diet\u2013induced NASH in mice: possible implication of FgfMPK signaling","volume":"71","author":"El-Agroudy","year":"2022","journal-title":"Diabetes"},{"issue":"512","key":"10.1016\/bs.pmbts.2023.12.005_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay0284","article-title":"Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates","volume":"11","author":"Goedeke","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molmed.2021.11.002","article-title":"Targeting ACC for NASH resolution","volume":"28","author":"Zhang","year":"2022","journal-title":"Trends Mol Med"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.005_bib90","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/cvr\/cvab034","article-title":"Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion","volume":"117","author":"Rogers","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"6478","key":"10.1016\/bs.pmbts.2023.12.005_bib91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK\u2013caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.005_bib92","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jpedsurg.2022.02.030","article-title":"The preventive effect of recombinant human hepatocyte growth factor for hepatic steatosis in a rat model of short bowel syndrome","volume":"57","author":"Yano","year":"2022","journal-title":"J Pediatric Surg"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.005_bib93","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20121689","article-title":"Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia","volume":"451","author":"Zammit","year":"2013","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.005_bib95","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tem.2015.12.001","article-title":"Mitochondrial dynamics and metabolic regulation","volume":"27","author":"Wai","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.005_bib96","first-page":"789","article-title":"Hepatocyte growth factor, adiponectin and hepatic histopathology in non-alcoholic steatohepatitis","volume":"61","author":"Agrawal","year":"2013","journal-title":"J Assoc Phys India"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib97","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jhep.2014.05.019","article-title":"Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice","volume":"61","author":"Kroy","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2014.03.028","article-title":"Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice","volume":"61","author":"Lazic","year":"2014","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.005_bib99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3934\/molsci.2015.4.427","article-title":"Cigarette smoke may be an exacerbation factor in nonalcoholic fatty liver disease via modulation of the PI3K\/AKT pathway","volume":"2","author":"Ichimura","year":"2015","journal-title":"AIMS Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.005_bib100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmgh.2014.11.005","article-title":"Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis","volume":"1","author":"Hirsova","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"}],"container-title":["Progress in Molecular Biology and Translational Science","RNA Therapeutics Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117323001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117323001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:08:50Z","timestamp":1753297730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117323001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443235443"],"references-count":100,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2023.12.005","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}